Cost and Resource Use of Pemphigus and Pemphigoid Disorders Pre- and Post-Rituximab

Rituximab for the first-line treatment of stage III–IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation.

(2014) D Papaioannou et al.   HEALTH TECHNOLOGY ASSESSMENT

Adjuvant rituximab therapy in pemphigus: a single-center experience of 18 cases

(2013) Sharon Baum et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

Cost–effectiveness of rituximab in follicular lymphoma

(2012) Karissa M Johnston et al.   Expert Review of Pharmacoeconomics & Outcomes Research

Pemphigoid diseases: Pathogenesis, diagnosis, and treatment

(2011) Michael Kasperkiewicz et al.   AUTOIMMUNITY

Pemphigus group (vulgaris, vegetans, foliaceus, herpetiformis, brasiliensis)

(2011) Pascal Joly et al.   CLINICS IN DERMATOLOGY

Cost-utility of different treatment strategies after the failure of tumour necrosis factor inhibitor in rheumatoid arthritis in the Finnish setting

(2010) T. A. Hallinen et al.   RHEUMATOLOGY

A review of the current use of rituximab in autoimmune diseases

(2008) Hakan M. Gürcan et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Budget impact model of rituximab after failure of one or more TNFα inhibitor therapies in the treatment of rheumatoid arthritis

(2008) Robert Launois et al.   JOINT BONE SPINE